Navigation Links
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Date:9/6/2007

LEUVEN, Belgium and LUND, Sweden, September 7 /PRNewswire/ --

- Decision Taken to Advance Novel, Long-Acting Anticoagulant Into Phase II Clinical Development

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, and co-development partner, BioInvent International (Nordic Exchange: BINV), announce today that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial of TB-402, which is being developed for the prevention of venous thromboembolic disorders (VTE - blood clots).

TB-402 is a recombinant human monoclonal antibody that targets factor VIII, a component of the coagulation cascade. This antibody is a promising novel anticoagulant agent particularly because it only partially inhibits factor VIII activity even when administrated in very high doses. This may potentially decrease the risk of undesirable bleedings and the need for monitoring, which are the main concerns associated with anticoagulants currently on the market.

The trial, performed in Denmark, was a randomized, single-dose, placebo-controlled, dose-escalation trial in healthy male volunteers. 56 volunteers were enrolled into the trial, including both younger age volunteers (18-45) and older age volunteers (55-76).

Preliminary results of the trial showed that TB-402 met both the primary (safety and tolerability) and secondary (pharmacokinetic and pharmacodynamic) endpoints. The drug was well tolerated and the study showed that TB-402's prolonged half-life will allow for single-dose treatment in orthopaedic surgery patients and/or once-a-month administration for long-term stroke prevention in atrial fibrillation (AF), as opposed to daily treatment with current anticoagulants. Importantly, the findings confirm that TB-402 achieves only partial inhibition of factor VIII activity without the undesired effect of total factor VIII inactivation. Final data analysis of the first Ph
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Until recently, pets suffering from arthritic ailments ... their pain. Pill therapies are costly, can be harmful ... , The procedure uses adult (not embryonic) animal ... regenerative healing power. MediVet's equipment enable veterinarians to remove ... stem cells, then activate and inject the cells into ...
(Date:9/11/2014)... 11, 2014  Ikonopedia will showcase its new ... imaging reporting modules here at the Intensive Breast ... Ikonopedia,s revolutionary suite of report generation software tools ... they look like rather than what they are ... reporting efficiency, and optimize facility operations.  ...
(Date:9/11/2014)... Florida (PRWEB) September 11, 2014 Central ... to announce his partnerships with several Brevard County animal ... Dr. Christiansen has been working in the area since ... small animals since 2008, and is happy to now ... the years Dr. Christiansen has used stem cell therapy ...
(Date:9/10/2014)... Jersey (PRWEB) September 11, 2014 ... its annual Innovations in Dermatological Sciences conference Oct. ... focus on how the university, industry and government ... into clinical use. , This conference is unique ... with cross-sector collaboration, to share their successes, best-practices, ...
Breaking Biology Technology:MediVet America Secures Exclusive Worldwide License with Nanofiber Veterinary 2Ikonopedia Showcases New MQSA Management System and Reporting Modules at Intensive Breast Ultrasound Meeting 2Ikonopedia Showcases New MQSA Management System and Reporting Modules at Intensive Breast Ultrasound Meeting 3Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... Pain From Rheumatoid Arthritis Despite Current Treatment; Findings ... Congress of Rheumatology , , COPENHAGEN, Denmark, ... Insights, Strategies & Expectations (RAISE) survey of more ... and Canada revealed a majority of patients still ...
... Strengthening the Molecular Bioassays Market , , ... its recent analysis of the molecular bioassays market, ... 2009 Frost & Sullivan North America Technology Innovation ... technology for cell surface receptor investigation, in particular ...
... Nektar Therapeutics (Nasdaq: NKTR ) today announced the ... Medical Officer. Dr. Masuoka reports to Nektar,s Senior Vice ... M.D., Ph.D. , , Dr. Masuoka has over ... As Chief Medical Officer, she will be instrumental in helping ...
Cached Biology Technology:New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 2New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 3New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 5New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 6Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 2Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 3Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 4Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 5Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer 2Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer 3
(Date:9/12/2014)... YORK and POINT ROBERTS, Washington ... Investorideas.com ( http://www.investorideas.com ) a global news source covering ... analysts and experts on the September 9 th launch ... of Goode Intelligence, Janice Kephart , founder of ... Gino Pereira of NXT-ID, Inc, (NASDAQ: NXTD ...
(Date:9/11/2014)... reduced frequency of social interactions and an increased ... has also been linked to dysfunction of the ... Now Caltech researchers have discovered antagonistic neuron populations ... animal engages in social behaviors or asocial repetitive ... neural circuit dysfunctions that underlie autism in humans. ...
(Date:9/11/2014)... DDT, American peregrine falcons ( Falco peregrines anatum ) ... stop rearing young birds in captivity and placing them ... models that year in ESA,s journal Ecological ... in California, with and without direct human intervention in ... would continue to recover without captive rearing, though the ...
Breaking Biology News(10 mins):Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5Tipping the balance of behavior 2Tipping the balance of behavior 3Volunteer 'eyes on the skies' track peregrine falcon recovery in California 2Volunteer 'eyes on the skies' track peregrine falcon recovery in California 3Volunteer 'eyes on the skies' track peregrine falcon recovery in California 4Volunteer 'eyes on the skies' track peregrine falcon recovery in California 5
... BOULDER--The shrinking expanse of Arctic sea ice is increasingly ... by scientists at the National Center for Atmospheric Research ... sunny weather contributed to last summer,s record loss of ... do not appear to have had comparable impacts. ...
... RELEASE Gel-like material shows promise as ... in Texas report development of a gel-like material that could ... taken in a pill by mouth, rather than with injections. ... ACS Biomacromolecules, a monthly journal. In the report, Nicholas ...
... 2008 Sonic,Innovations, Inc. (Nasdaq: SNCI ) a ... anniversary during 2008., The company is the largest ... the company,s revenue is generated from,outside the United States ... just 10 years Sonic Innovations has leveraged its world ...
Cached Biology News:Arctic ice more vulnerable to sunny weather, new study shows 2Arctic ice more vulnerable to sunny weather, new study shows 3American Chemical Society's Weekly PressPac -- April 16, 2008 2American Chemical Society's Weekly PressPac -- April 16, 2008 3American Chemical Society's Weekly PressPac -- April 16, 2008 4American Chemical Society's Weekly PressPac -- April 16, 2008 5American Chemical Society's Weekly PressPac -- April 16, 2008 6American Chemical Society's Weekly PressPac -- April 16, 2008 7American Chemical Society's Weekly PressPac -- April 16, 2008 8Sonic Innovations Celebrates 10-Year Anniversary 2Sonic Innovations Celebrates 10-Year Anniversary 3
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
...
Biology Products: